Perrimustine

Perrimustine is a cysteamine (CysA) derivative with potent antitumor activity. Perrimustine exhibits significant effect on B16 melanoma and metastasized melanoma cells by causing DNA damage. Perrimustine exhibits antitumor effects in mice bearing various cancers, including lung carcinoma, leukemia, lymphoma, melanoma, colon carcinoma, and glioma. Perrimustine can be used for cancer research, such as melanoma and leukemia[1][2].

Product Specifications

CAS Number

[96413-13-7]

UNSPSC

12352211

Target

Drug Derivative

Related Pathways

Others

Field of Research

Cancer

Smiles

CS(CCNC(N(N=O)CCCl)=O)=O

Molecular Formula

C6H12ClN3O3S

Molecular Weight

241.70

References & Citations

[1]Kim-Triana B, et al. Phase I trial of Perrimustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme. Anticancer Drugs. 1992 Jun;3 (3) :225-31.|[2]Godeneche D, et al. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells. Cancer Res. 1990 Sep 15;50 (18) :5898-903.